Latest North America News

Gladiator Resources has initiated the process to list on the US OTC Markets, aiming to enhance visibility and liquidity among North American investors as part of its rare earth elements growth strategy.

Structural Monitoring Systems plc has reported its first profit after tax, driven by strong avionics sales and a successful $8.7 million capital raise. The company’s strategic shift towards proprietary products and key certifications underpin a positive outlook.

Control Bionics Limited reported a 14.8% revenue increase to $6.14 million for FY2025 but also a 3.3% rise in net loss to $6.11 million, while pursuing a $2 million rights issue and expanding its investment portfolio.

Sayona Mining delivered record lithium production and sales in FY25 but reported a $382 million loss due to asset impairments amid falling lithium prices. The company is poised for transformation with its imminent merger with Piedmont Lithium.

Wiseway Group has delivered its strongest financial performance since listing, powered by a booming US division and a sharp focus on eCommerce imports across key markets.

Future Generation Global Limited reported a notable decline in half-year profits but raised its fully franked interim dividend, underscoring confidence in its investment strategy and ongoing commitment to youth mental health initiatives.

FINEOS Corporation Holdings PLC reports solid half-year growth with rising subscription revenue and improved margins, while navigating currency challenges. The company remains confident in achieving positive free cash flow for FY25 and advancing its AI and cloud strategies.

FINEOS Corporation Holdings plc reported a 4.2% increase in revenue to €67.1 million for H1 2025, alongside a significant 76% reduction in losses, driven by subscription growth and operational efficiencies.

EMVision Medical Devices reported a sharp increase in FY25 losses alongside a 51% revenue drop, yet marked significant progress in clinical trials for its innovative brain scanners and secured $8 million in government grants to fuel commercialisation.

Clinuvel Pharmaceuticals reports steady financial growth with an 8% rise in revenue and 2% profit increase, while expanding its US commercial footprint and completing recruitment for a pivotal vitiligo trial.

SomnoMed delivered a strong FY25 performance with revenue climbing 22% to $111.5 million and EBITDA turning positive at $9.2 million, boosted by operational improvements and FDA clearance of its Rest Assure device. The company projects further growth in FY26 with expanded manufacturing and ongoing innovation.

SomnoMed has delivered a standout FY25 with revenue and EBITDA exceeding market expectations, driven by strong regional growth and operational improvements. The company is now expanding capacity and advancing its innovative Rest Assure device.